Disease · MONDO_0100114
dry age related macular degeneration
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. dry age related macular degeneration. Diseases, record MONDO_0100114. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0100114
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- dry age related macular degeneration
- Open Targets ID
- MONDO_0100114
- Other names
- dry AMD, dry ARMD
- Highest stage of its drugs
- Phase 3, for 2 of its 7 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs7
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ANECORTAVE ACETATE | CHEMBL2106613 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ELAMIPRETIDE | CHEMBL3833370 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| AVACINCAPTAD PEGOL | CHEMBL6068573 | Oligonucleotide | Phase 2/3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| RANIBIZUMAB | CHEMBL1201825 | Antibody | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| EMIXUSTAT HYDROCHLORIDE | CHEMBL2107829 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CURCUMIN | CHEMBL140 | Small molecule | Early phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BEVACIZUMAB | CHEMBL1201583 | Antibody | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets2
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| VEGFA | Vascular endothelial growth factor A, long form | 2 | Vascular endothelial growth factor A inhibitor | Phase 2 | https://conductscience.org/library/genes/7422 | Drugs and targets |
| RPE65 | Retinoid isomerohydrolase | 1 | Retinoid isomerohydrolase inhibitor | Phase 1 | https://conductscience.org/library/genes/6121 | Drugs and targets |
Trials8
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02686658 | Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | Phase 2/3 | 286 | 2023-05-11 | Geographic Atrophy, Dry Age-Related Macular Degeneration | AVACINCAPTAD PEGOL | Its record names the disease | ClinicalTrials.gov |
| NCT00931489 | Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD) | Phase 2 | 131 | 2017-07-02 | Age Related Macular Degeneration | RANIBIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT06373731 | ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD) | Phase 3 | 313 | Age Related Macular Degeneration (ARMD) | ELAMIPRETIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT00727753 | VEGF-antagonism and Endothelial Function in Age-related Macular Degeneration (AMD) | 54 | Macular Degeneration | BEVACIZUMAB, RANIBIZUMAB | Its record names the disease | ClinicalTrials.gov | ||
| NCT00950638 | A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration | Phase 1 | 47 | Dry Age-Related Macular Degeneration | AVACINCAPTAD PEGOL | Its record names the disease | ClinicalTrials.gov | |
| NCT00332657 | Anecortave Acetate Risk Reduction Trial (AART) | Phase 3 | 36 | AMD | ANECORTAVE ACETATE | Its record names the disease | ClinicalTrials.gov | |
| NCT02130531 | Pharmacokinetic and Pharmacodynamic Study of Emixustat in Subjects With Geographic Atrophy Associated With Dry Age-Related Macular Degeneration | Phase 1 | 26 | Geographic Atrophy, Age-Related Macular Degeneration | EMIXUSTAT HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT04590196 | Effect of Oral Curcumin Supplementation in Dry Age-related Macular Degeneration (AMD) Patients | Early phase 1 | 10 | Age Related Macular Degeneration | CURCUMIN | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials3
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0100114
GET https://conductscience.org/api/diseases/v1/MONDO_0100114/drugs